JBM (Healthcare) Limited

SEHK:2161 Stock Report

Market Cap: HK$1.5b

JBM (Healthcare) Past Earnings Performance

Past criteria checks 5/6

JBM (Healthcare) has been growing earnings at an average annual rate of 52.6%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 22.1% per year. JBM (Healthcare)'s return on equity is 16.1%, and it has net margins of 22.7%.

Key information

52.6%

Earnings growth rate

51.2%

EPS growth rate

Pharmaceuticals Industry Growth5.6%
Revenue growth rate22.1%
Return on equity16.1%
Net Margin22.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

JBM (Healthcare)'s (HKG:2161) Earnings Are Weaker Than They Seem

Dec 20
JBM (Healthcare)'s (HKG:2161) Earnings Are Weaker Than They Seem

Recent updates

JBM (Healthcare) Limited (HKG:2161) Stock Rockets 35% But Many Are Still Ignoring The Company

Nov 08
JBM (Healthcare) Limited (HKG:2161) Stock Rockets 35% But Many Are Still Ignoring The Company

JBM (Healthcare)'s (HKG:2161) Earnings Are Weaker Than They Seem

Dec 20
JBM (Healthcare)'s (HKG:2161) Earnings Are Weaker Than They Seem

Here's Why JBM (Healthcare) (HKG:2161) Has Caught The Eye Of Investors

Nov 01
Here's Why JBM (Healthcare) (HKG:2161) Has Caught The Eye Of Investors

JBM (Healthcare) Limited's (HKG:2161) Shares May Have Run Too Fast Too Soon

Jul 29
JBM (Healthcare) Limited's (HKG:2161) Shares May Have Run Too Fast Too Soon

Some Investors May Be Willing To Look Past JBM (Healthcare)'s (HKG:2161) Soft Earnings

Aug 03
Some Investors May Be Willing To Look Past JBM (Healthcare)'s (HKG:2161) Soft Earnings

Estimating The Fair Value Of JBM (Healthcare) Limited (HKG:2161)

Jul 28
Estimating The Fair Value Of JBM (Healthcare) Limited (HKG:2161)

Revenue & Expenses Breakdown

How JBM (Healthcare) makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SEHK:2161 Revenue, expenses and earnings (HKD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 247211641820
30 Jun 246841471810
31 Mar 246481301800
31 Dec 236291141750
30 Sep 23610981700
30 Jun 23565781540
31 Mar 23520571380
31 Dec 22487471300
30 Sep 22454361220
30 Jun 22430301220
31 Mar 22406251230
31 Dec 21398181240
30 Sep 21390111260
30 Jun 21394171270
31 Mar 21397231280
31 Mar 20382411390
31 Mar 19308521070
31 Mar 1826442950

Quality Earnings: 2161 has high quality earnings.

Growing Profit Margin: 2161's current net profit margins (22.7%) are higher than last year (16.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 2161's earnings have grown significantly by 52.6% per year over the past 5 years.

Accelerating Growth: 2161's earnings growth over the past year (67.2%) exceeds its 5-year average (52.6% per year).

Earnings vs Industry: 2161 earnings growth over the past year (67.2%) exceeded the Pharmaceuticals industry 9.4%.

Return on Equity

High ROE: 2161's Return on Equity (16.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 00:25
End of Day Share Price 2025/01/28 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

JBM (Healthcare) Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xiao Qin DouUOB Kay Hian Research Pte Ltd
Gigi CheukUOB Kay Hian Research Pte Ltd